Yan Chen, MD, PhD, Elpis Biopharmaceuticals, Boston, MA, discusses upcoming projects, including research into multispecific or multifunctional cell therapy products, leveraging two technology platforms for antibody discovery and cytokine engineering. For instance, these technologies have been utilised for precision engineering of tumor-targeting cytokines. Another important research focus is multispecific or multifunctional antibodies. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.